Personalized Translational Platform for Biomarker Discovery in Brain Tumors

Completed

Conditions studied: High Grade Glioma

In brief

The central hypothesis for this proposal is that multimodal (clinical, imaging, tissue) biomarkers will better predict early brain tumor response to treatments and will be more reliable prognostic markers in patients with malignant brain tumors.

Key facts

Study ID

NCT01240161

Run by

Marcelo F. Di Carli, MD, FACC

People needed

37

Starts

2009-12-01

Expected to finish

2016-03-01

Last updated by the study team

2017-08-29

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Newly diagnosed or suspected high grade glioma ≥ 1cm in diameter on postoperative anatomic imaging (contrast MRI), prior to initiation of chemoXRT
• Anticipated survival ≥6 months
• Able to give informed consent
• Capable of undergoing MRI and PET scans without the need for sedation or general anesthesia
• Male or Female

You may not qualify if…

• Prior radiation therapy and chemotherapy to the brain
• Active intracranial infection or nonglial brain mass.
• Recent large intracranial hemorrhage (<1 month)
• Expected survival <6 months
• Pregnant or nursing
• Renal failure
• Lives far from BWH and/or is unwilling/ unable to return for scheduled imaging visits.

Where it is running

• University of California at San Diego — San Diego, California, United States
• Brigham and Women's Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.